SOUTHWEST ONCOLOGY GROUP

西南肿瘤集团

• 批准号: 6854994
• 负责人: LAWRENCE E FLAHERTY
• 金额: $ 8.04万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-01-01 至 2004-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6854994
• 关键词: antineoplastics; bleomycin; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer information system; cancer prevention; cancer registry /resource; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; female reproductive system neoplasm; fludarabine; gastrointestinal neoplasms; head /neck neoplasm; hormone therapy; human subject; human therapy evaluation; ifosfamide; leukemia; lung neoplasms; lymphoma; meeting /conference /symposium; melanoma; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; oncology nursing; paclitaxel; pancreas neoplasms; pathology; prognosis; prostate neoplasms; quality of life; sarcoma; tamoxifen; tissue resource /registry; urinary tract neoplasms; women' s health

Description (Adapted from the applicant's abstract): Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 25 years, enrolling over 4500 patients onto clinical trials. Over these years, their faculty have played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution's performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Thus, their faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment towards those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities, are easily facilitated. In addition, the demographics of their region and the commitment of investigators to make clinical trials available to all patients, is clearly identified in their recruitment of minorities (33 percent) and women (46 percent) into SWOG clinical trials. The SWOG membership in WSU and the diversity of disciplinary involvement by their faculty has continued to grow over the years. To date, 87 WSU members are currently serving on 38 committees. Similarly, 60 SWOG studies list a WSU member as a study chairman or as study coordinator since the last competing application was submitted. Dr. Lawrence Flaherty, a SWOG member since 1986 and Vice-Chairman of the SWOG Melanoma Committee, becomes the Principal Investigator of this competing renewal at the departure of Dr. Manuel Valdivieso for another institution. He will maintain the prominence of WSU as a SWOG member institution.

描述（改编自申请人的摘要）：韦恩州立大学 （WSU）一直是西南肿瘤学的活跃机构成员 组超过25年，将4500多名患者纳入临床试验。 这些年来，他们的教师在支持方面发挥了重要作用 通过在行政和科学职能方面提供领导才能摇摆 扭曲，以及通过满足并超越患者的应计目标 连续且一致的方式。 因此，WSU一直保持在第一个 机构的绩效评估四分之一 过去五年。 WSU的癌症临床研究计划 沿着多学科疾病的研究进行组织 并以类似于器官委员会屈服的方式。 因此，他们的教师在科学摇摆委员会中的代表是 由具有专业知识和对这些领域承诺的个人组成 研究。 因此，将思想转化为摇摆研究 以及吞噬研究的融合以及NCI指定高的研究 优先级试验将纳入WSU治疗优先级，很容易促进。 在 此外，该地区的人口统计及其承诺 调查人员对所有患者进行临床试验，显然是 在招募少数民族（33％）和妇女（46个 百分比）进入临床试验。 WSU和 教师的学科参与的多样性继续增长 历年。 迄今为止，目前有87个WSU成员在38个 委员会。 同样，60个SWOG研究将WSU成员列为一项研究 自上次竞争申请以来，主席或作为学习协调员 提交。 劳伦斯·弗莱厄蒂（Lawrence Flaherty）博士，自1986年以来一直是Swog成员， SWOG黑色素瘤委员会副主席成为校长 曼努埃尔博士离开时，这种竞争更新的调查员 Valdivieso为另一个机构。 他将保持WSU的突出 作为一家吞噬会员机构。